Dianthus Therapeutics, Inc. /DE/ Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2022-02-14: Study NCT05223699; Company role Lead sponsor; Phase Phase 1; Status Terminated.
- 2019-05-21: Study NCT04008849; Company role Lead sponsor; Phase Observational; Status Terminated.
- 2018-02-09: Study NCT03406962; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2022-02-14 | NCT05223699 Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | Lead sponsor | Phase 1 | Terminated | Acute Myeloid Leukemia; Myelodysplasia | 22 | 2023-02-02 |
| 2019-05-21 | NCT04008849 A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456 | Lead sponsor | Observational | Terminated | Inherited Metabolic Disorders (IMD) | 3 | 2020-10-08 |
| 2018-02-09 | NCT03406962 MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) | Lead sponsor | Phase 2 | Completed Results posted | Inherited Metabolic Disorders (IMD) | 8 | 2021-01-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |